IRI Separation Technologies Inc.
TSX VENTURE : IRI

IRI Separation Technologies Inc.

June 14, 2007 08:30 ET

IRI Separation Technologies Hires Chief Marketing Officer

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 14, 2007) - IRI Separation Technologies Inc. (TSX VENTURE:IRI) announced today the hiring of Ron Bayne as Chief Marketing Officer. Ron has signed a two year management contract with IRI Separation and will co-ordinate sales with raw material purchasers. He will also oversee the marketing of the Ig product to his extensive network in both Canada and the US.

Ron has more than 40 years of experience in marketing packaged goods to pharmacies and has overseen the marketing of more than 300 private label products. Ron has been directly involved with eight different retail chains (with a total of almost 2,000 stores) and brings with him strong relationships with more than 75 sales agents in Canada and the Western United States.

"We are very pleased to welcome Ron Bayne," stated John Mason, President and CEO of IRI Separation. "Ron's experience and creativity is welcomed and will bring unprecedented expertise to our management team."

Ron has worked with such retail drug chains as People's Drug Mart, Western Drug Mart, Tamblyn's DrugMart, Good Neighbor Pharmacies (Winnipeg), ARP Pharmacies (Winnipeg), United Pharmacy (Saskatoon), Community Drug Marts (BC), and V.P. Retail Operations National Drugs where he oversaw the development and marketing of the various store brand lines of vitamins, health & beauty products and over the counter drugs.

About IRI Separation Technologies Inc.

IRI Separation Technologies Inc. (TSX VENTURE:IRI) is a biotechnology company that specializes in the extraction, development and commercialization of monoclonal and polyclonal immunoglobulin antibodies for virus and bacteria related health issues. Intended for use as a nutraceutical for human consumption, the antibodies are derived from bovine whey and chicken eggs. The immunoglobulin antibodies are intended for both the general and specific antibody market.

On behalf of the Board of Directors, John Mason, President and CEO

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Ascenta Capital Partners Inc.
    Keir Reynolds
    Investor Relations
    (604) 628-5800 or Toll Free: 1-866-684-4209
    Email: keir@ascentacapital.com
    or
    IRI Separation Technologies Inc.
    John Mason
    (604) 807-8694
    (604) 926-1485 (FAX)
    Email: jmason99@shaw.ca